{"filings":[{"id":746530,"accession_number":"0001193125-26-248242","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-05-29T20:05:14+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Acadia shareholders approve 5.2M-share increase to 2024 equity plan, re-elect three Class I directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 5,209,670.","Re-elected Class I directors James M. Daly, Edmund P. Harrigan, and Adora Ndu to Board until 2029.","Advisory vote on executive compensation approved with 98.7% of votes cast in favor.","Ernst & Young ratified as independent auditor for FY2026 with 157,409,378 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91085,"accession_number":"0001193125-26-209253","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q1 revenue $268M (+10% YoY); DAYBUE sales $101M (+20%); reaffirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Total Q1 revenues $268M (+10% GAAP YoY, +11% adj); NUPLAZID $167M (+5% GAAP, +6% adj); DAYBUE $101M (+20%).","DAYBUE STIX launch underway; ~30% of STIX patients treatment-naive or returning after liquid discontinuation.","Phase 2 remlifanserin topline data in Alzheimer's disease psychosis expected Aug–Oct 2026, on track.","Trofinetide Japan trial results anticipated Sep–Nov 2026; Delphi panel recommends DAYBUE as Rett syndrome standard of care.","Reaffirms full-year 2026 financial guidance (no specific numbers provided)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":268062000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91084,"accession_number":"0001193125-26-197957","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Acadia R&D Head Elizabeth Thompson plans retirement; stays through 2026 as consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Thompson will retire for personal reasons; remains as Head of R&D until successor appointed, then consultant through end of 2026.","She will stay through readout of Phase 2 remlifanserin in Alzheimer's disease psychosis and into early Phase 3.","Company has initiated a search for a new Head of R&D; all ongoing clinical trials continue as planned.","Thompson joined Acadia in 2024 and helped strengthen clinical capabilities and advance pipeline programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100994,"accession_number":"0001193125-26-092213","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Acadia Pharmaceuticals appoints Jonathan M. Poole to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Poole appointed effective March 3, 2026 as Class II director, term expiring at 2027 annual meeting.","He will serve on the Audit Committee; receives $50k annual cash retainer plus $12.5k for committee role.","Initial equity grant with $200k target fair value (split options/RSUs); prorated annual grant of $95,300.","Future annual equity grants of $400k (half options, half RSUs) with quarterly vesting over one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100993,"accession_number":"0001193125-26-071674","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q4 2025 GAAP revenue $284M; FY25 $1.07B; NUPLAZID $174M, DAYBUE $110M; FY26 guidance $1.22-1.28B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 GAAP total revenue $284M; non-GAAP adjusted $298M (+16% YoY); FY25 GAAP $1.07B, non-GAAP $1.08B.","GAAP NUPLAZID net sales $174M (includes $20M IRA rebate adjustment); non-GAAP adjusted $189M, up 17% vs Q4 2024.","DAYBUE net sales $110M in Q4 (+13% YoY) and $391M for FY25.","Net income Q4 $274M ($1.60 diluted EPS) including $250M tax benefit; FY net income $391M ($2.30 EPS). Cash & investments $820M.","FY 2026 guidance: total revenue $1.22-1.28B; NUPLAZID $760-790M; DAYBUE $460-490M; R&D $385-410M; SG&A $660-700M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":1071505000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100992,"accession_number":"0001193125-26-011706","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Acadia Pharmaceuticals reaffirms 2025 net sales guidance above $1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance.","Presented at J.P. Morgan Healthcare Conference on January 13, 2026.","Corporate slide presentation posted on ir.acadia.com for investor access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117321,"accession_number":"0001193125-25-266959","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q3 revenue $278.6M (+11% YoY); net income $71.8M; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product sales: NUPLAZID $177.5M (+12% YoY), DAYBUE $101.1M (+11% YoY).","Q3 net income $71.8M ($0.42 diluted EPS) vs. $32.8M ($0.20) in Q3 2024.","Full-year 2025 total revenue guidance raised to $1.07-1.095B from $1.045-1.095B.","NUPLAZID guidance raised to $685-695M; DAYBUE guidance tightened to $385-400M.","Cash & investments $847M at Sept 30, 2025 vs. $756M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":787516000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117320,"accession_number":"0001193125-25-262610","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Daniel B. Soland resigns from Acadia board and governance committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation effective October 30, 2025.","Mr. Soland stepped down from the Board and as Chair of Nominating and Corporate Governance Committee.","Resignation not due to any dispute or disagreement with the Company or Board.","No replacement for the Board seat or committee chair has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133757,"accession_number":"0000950170-25-104092","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q2 revenue $264.6M (+9% YoY); NUPLAZID guidance raised to $665-690M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $264.6M, NUPLAZID $168.5M (+7%), DAYBUE $96.1M (+14%).","Net income $26.7M ($0.16 EPS) vs $33.4M ($0.20 EPS) YoY due to higher tax rate.","Raised NUPLAZID net sales guidance low end to $665M; total revenue guidance $1.045-1.095B.","Patent litigation wins affirm NUPLAZID exclusivity through 2030 (composition) and 2038 (formulation).","COMPASS PWS Phase 3 study enrollment complete; top-line results expected early Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":508882000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150480,"accession_number":"0001193125-25-138452","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Federal Circuit affirms Acadia's NUPLAZID patent validity in MSN litigation","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. Court of Appeals affirmed District Court decision confirming validity of Acadia's '740 composition of matter patent for NUPLAZID (pimavanserin).","Ruling came in patent litigation against MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc.","Protects Acadia's intellectual property for NUPLAZID, used to treat Parkinson's disease psychosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150479,"accession_number":"0001193125-25-130620","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acadia shareholders elect three Class III directors, approve say-on-pay, ratify EY auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Catherine Owen Adams, Laura A. Brege, and Elizabeth A. Garofalo, M.D. as Class III directors; each received >129M votes for.","Advisory vote on named executive officer compensation approved: 142.2M for, 2.8M against, 108.8K abstain.","Ernst & Young LLP ratified as independent auditor for FY2025: 154.5M for, 926.5K against, 35.0K abstain.","Broker non-votes of 10.3M shares on director election and advisory compensation vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150478,"accession_number":"0001193125-25-123175","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"Acadia wins patent litigation for NUPLAZID; court rules for Acadia on infringement and validity","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Delaware ruled in Acadia's favor in Pimavanserin II Cases regarding '721 formulation patent for NUPLAZID.","Court ruled for Acadia on both infringement and validity arguments against Aurobindo Pharma and MSN Laboratories.","Acadia entered a 12-year lease for ~52,771 sq ft Princeton executive office; 210 Lease starts by Jan 2026 with $1.9M first-year rent.","Amended current 502 Lease to terminate 5 days after 210 Lease commencement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150477,"accession_number":"0000950170-25-065672","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q1 revenue +19% to $244.3M; net income $19M; ACP-101 results accelerated to Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q1 revenue $244.3M, up 19% YoY; NUPLAZID sales $159.7M (+23%), DAYBUE $84.6M (+11%)","Net income $19.0M ($0.11/sh) vs $16.6M ($0.10/sh) in Q1 2024; cash $681.6M","DAYBUE record 954 unique patients shipped; 30% field force expansion completed; first EU patient served","COMPASS PWS Phase 3 topline results now expected early Q4 2025 (accelerated); if positive, NDA submission Q1 2026","2025 guidance reiterated: total rev $1.03-1.095B; R&D expense raised to $330-350M due to study acceleration"],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":244317000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150476,"accession_number":"0001193125-25-082809","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Acadia Pharmaceuticals amends bylaws, tightens stockholder nomination and meeting rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum threshold changed from majority of outstanding shares to majority of voting power.","Stockholder nominees limited to number of directors to be elected; substitute nominees prohibited.","Advance notice window widened: alternative window applies if annual meeting delayed >70 days (was 30).","Mandatory indemnification and expense advancement for directors/officers expanded to maximum extent allowed.","Exclusive forum provisions clarified, including U.S. federal district courts for Securities Act claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169449,"accession_number":"0000950170-25-027759","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q4 net income $143.7M; FY2024 revenue $957.8M (+32%); guides FY2025 rev $1.03-1.095B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total net product sales $957.8M, up 32% YoY; NUPLAZID $609.4M (+11%), DAYBUE $348.4M (+97%).","Q4 net income $143.7M ($0.86 EPS) vs $45.8M ($0.28 EPS) in Q4 2023; includes $146.5M PRV sale gain.","FY2024 net income $226.5M ($1.37 EPS) vs net loss of $61.3M ($0.37 loss per share) in FY2023.","FY2025 guidance: total revenue $1.03-1.095B; NUPLAZID $650-690M; DAYBUE $380-405M; R&D $310-330M; SG&A $535-565M.","Cash and investments $756.0M at Dec 31, 2024, up from $438.9M; EMA submission for trofinetide completed."],"consensus_eps_estimate":null,"consensus_eps_actual":1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":957797000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186501,"accession_number":"0001193125-24-275595","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Acadia sells Rare Pediatric Disease PRV for $150M, one third to partner Neuren","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of PRV for $150M on Dec 11, 2024, after HSR waiting period expired.","PRV awarded March 2023 from FDA approval of DAYBUE (trofinetide) for Rett syndrome.","One third of net proceeds payable to Neuren under July 2023 joint venture agreement.","Material terms of PRV Transfer Agreement previously disclosed in Q3 2024 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186500,"accession_number":"0001193125-24-262556","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Acadia Pharma terminates COO Brendan Teehan without cause; CEO assumes duties","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brendan Teehan, EVP, COO and Head of Commercial, involuntarily terminated without Cause effective Nov 18, 2024.","Teehan will remain a non-executive employee until Dec 31, 2024 to assist transition.","CEO Catherine Owen Adams, with 30+ years pharma commercial experience, will assume his responsibilities until a successor is appointed.","No successor has been named; search for replacement is underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186499,"accession_number":"0000950170-24-122322","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q3 total revenue $250.4M (+18% YoY); net income $32.8M vs year-ago loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NUPLAZID sales $159.2M (+10% YoY); DAYBUE sales $91.2M (+36% YoY).","Net income $0.20 per share vs ($0.40) loss; nine-month net income $82.7M.","Full-year guidance: NUPLAZID $600-610M, DAYBUE $340-350M, total revenue $940-960M.","Entered agreement to sell Rare Pediatric Disease PRV for $150M; one-third of net to Neuren.","Health Canada approved DAYBUE for Rett syndrome under Priority Review."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":698195000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203079,"accession_number":"0001193125-24-223726","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Acadia CEO Stephen R. Davis terminated Sept 23; Catherine Owen Adams appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen R. Davis involuntarily terminated without cause as President and CEO effective Sept 23, 2024; resigns from board.","Davis receives severance: 1.5x base+target bonus, pro-rata 2024 bonus, 12 months accelerated equity, 18 months COBRA.","Catherine Owen Adams appointed CEO and director effective Sept 23; previously SVP and GM U.S. at BMS overseeing $20B business.","Adams compensation: $900k base salary, 80% target bonus, $500k sign-on, plus equity awards of $3.25M in options and $3.25M in PSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203078,"accession_number":"0000950170-24-091826","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q2 total revenue up 46% to $242M; net income $33.4M vs $1.1M last year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NUPLAZID net sales $157.4M (+11% YoY); DAYBUE net sales $84.6M (vs $23.2M YoY).","Net income $33.4M ($0.20 EPS) vs $1.1M ($0.01 EPS) in Q2 2023.","NUPLAZID FY guidance raised to $590-610M; DAYBUE lowered to $340-370M.","Total revenue FY guidance revised to $930-980M (from $930M-$1.01B).","Cash and investments $500.9M at June 30, 2024, up from $438.9M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":447794000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219369,"accession_number":"0001193125-24-149336","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Acadia shareholders elect directors, approve 2024 equity plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Julian C. Baker, Stephen R. Biggar, and Daniel B. Soland elected as Class II directors.","2024 Equity Incentive Plan approved with 131.3M votes for, 9.4M against.","Say-on-pay advisory vote passed with 132.99M for, 7.64M against.","Ernst & Young ratified as independent auditor for FY2024 with 150.0M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219368,"accession_number":"0000950170-24-055647","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Q1 revenue $205.8M (+74% YoY), net income $16.6M vs loss year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NUPLAZID net sales $129.9M (+10% YoY); DAYBUE net sales $75.9M (vs $0 in Q1 2023)","Net income of $16.6M ($0.10 EPS) compared to net loss of $43.0M ($0.27 loss) in Q1 2023","Full-year 2024 guidance reiterated: DAYBUE $370-420M, NUPLAZID $560-590M","Cash and investments $470.5M at quarter end, up from $438.9M at Dec 31 2023","Appointed Elizabeth H.Z. Thompson as EVP, Head of R&D"],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":205831000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239199,"accession_number":"0001193125-24-064791","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ACAD's Phase 3 ADVANCE-2 trial of pimavanserin misses primary endpoint in negative symptoms of schizophrenia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pimavanserin failed Phase 3 ADVANCE-2 trial for negative symptoms of schizophrenia; primary endpoint not met.","Safety and tolerability consistent with prior trials, showing low adverse event rate.","No financial or regulatory guidance provided in this 8-K; further analysis may follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239198,"accession_number":"0000950170-24-021169","cik":1070494,"company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acadia Pharma Q4 net income $45.8M; 2023 revenue $726.4M (+40%); FY2024 DAYBUE guide $370-420M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net income $45.8M ($0.28 EPS) vs net loss $41.7M ($0.26 loss) in Q4 2022.","Full year 2023 net loss $61.3M ($0.37 loss) vs net loss $216.0M ($1.34 loss) in 2022.","2023 total net product sales $726.4M (+40% YoY); DAYBUE $177.2M, NUPLAZID $549.2M (+6%).","FY2024 guidance: DAYBUE net sales $370-420M; NUPLAZID $560-590M; R&D $305-325M; SG&A $455-480M.","Phase 3 ADVANCE-2 (pimavanserin for negative schizophrenia) top-line results due by end of Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":726437000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3628488131.9459076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}